204 related articles for article (PubMed ID: 29685114)
21. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
22. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
[TBL] [Abstract][Full Text] [Related]
23. Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.
Abubakar I; Pimpin L; Ariti C; Beynon R; Mangtani P; Sterne JA; Fine PE; Smith PG; Lipman M; Elliman D; Watson JM; Drumright LN; Whiting PF; Vynnycky E; Rodrigues LC
Health Technol Assess; 2013 Sep; 17(37):1-372, v-vi. PubMed ID: 24021245
[TBL] [Abstract][Full Text] [Related]
24. Motivations of patients with pulmonary arterial hypertension to participate in randomized clinical trials.
Carroll R; Antigua J; Taichman D; Palevsky H; Forfia P; Kawut S; Halpern SD
Clin Trials; 2012 Jun; 9(3):348-57. PubMed ID: 22388077
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.
Lahey T; Laddy D; Hill K; Schaeffer J; Hogg A; Keeble J; Dagg B; Ho MM; Arbeit RD; von Reyn CF
PLoS One; 2016; 11(12):e0168521. PubMed ID: 27997597
[TBL] [Abstract][Full Text] [Related]
26. [Advances in the development of new vaccines against tuberculosis. 100 years after the introduction of BCG].
Krysztopa-Grzybowska K; Lutyńska A
Postepy Hig Med Dosw (Online); 2014 Jun; 68():768-76. PubMed ID: 24934535
[TBL] [Abstract][Full Text] [Related]
27. Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine.
Gupta N; Garg S; Vedi S; Kunimoto DY; Kumar R; Agrawal B
Front Immunol; 2018; 9():2371. PubMed ID: 30386336
[TBL] [Abstract][Full Text] [Related]
28. Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial.
Spertini F; Audran R; Chakour R; Karoui O; Steiner-Monard V; Thierry AC; Mayor CE; Rettby N; Jaton K; Vallotton L; Lazor-Blanchet C; Doce J; Puentes E; Marinova D; Aguilo N; Martin C
Lancet Respir Med; 2015 Dec; 3(12):953-62. PubMed ID: 26598141
[TBL] [Abstract][Full Text] [Related]
29. Motivators and barriers influencing willingness to participate in candidate HCV vaccine trials: perspectives of people who inject drugs.
Park JN; White B; Bates A; Enriquez J; Liao L; Maher L
Drug Alcohol Depend; 2012 Jun; 123(1-3):35-40. PubMed ID: 22071117
[TBL] [Abstract][Full Text] [Related]
30. Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?
Khademi F; Derakhshan M; Yousefi-Avarvand A; Tafaghodi M; Soleimanpour S
Expert Rev Vaccines; 2018 Jan; 17(1):31-44. PubMed ID: 29148853
[TBL] [Abstract][Full Text] [Related]
31. BCG vaccine effectiveness in preventing tuberculosis and its interaction with human immunodeficiency virus infection.
Arbeláez MP; Nelson KE; Muñoz A
Int J Epidemiol; 2000 Dec; 29(6):1085-91. PubMed ID: 11101552
[TBL] [Abstract][Full Text] [Related]
32. Adolescent decision making about participation in a hypothetical HIV vaccine trial.
Alexander AB; Ott MA; Lally MA; Sniecinski K; Baker A; Zimet GD;
Vaccine; 2015 Mar; 33(11):1331-7. PubMed ID: 25645175
[TBL] [Abstract][Full Text] [Related]
33. Tuberculosis vaccine: time to look into future.
Chawla S; Garg D; Jain RB; Khanna P; Choudhary S; Sahoo S; Singh I
Hum Vaccin Immunother; 2014; 10(2):420-2. PubMed ID: 24231233
[TBL] [Abstract][Full Text] [Related]
34. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
35. South Asian patients' views and experiences of clinical trial participation.
Hussain-Gambles M
Fam Pract; 2004 Dec; 21(6):636-42. PubMed ID: 15528290
[TBL] [Abstract][Full Text] [Related]
36. A review of the literature on the economics of vaccination against TB.
Tu HA; Vu HD; Rozenbaum MH; Woerdenbag HJ; Postma MJ
Expert Rev Vaccines; 2012 Mar; 11(3):303-17. PubMed ID: 22380823
[TBL] [Abstract][Full Text] [Related]
37. A 2-Dose AERAS-402 Regimen Boosts CD8
Sivakumaran D; Blatner G; Bakken R; Hokey D; Ritz C; Jenum S; Grewal HMS
Front Immunol; 2021; 12():673532. PubMed ID: 34177914
[TBL] [Abstract][Full Text] [Related]
38. Is a new tuberculosis vaccine necessary and feasible? A Cuban opinion.
Sierra VG
Tuberculosis (Edinb); 2006; 86(3-4):169-78. PubMed ID: 16677860
[TBL] [Abstract][Full Text] [Related]
39. Patients' reasoning regarding the decision to participate in clinical cancer trials: an interview study.
Dellson P; Nilsson K; Jernström H; Carlsson C
Trials; 2018 Sep; 19(1):528. PubMed ID: 30268150
[TBL] [Abstract][Full Text] [Related]
40. Strategies to reach and motivate migrant communities at high risk for TB to participate in a latent tuberculosis infection screening program: a community-engaged, mixed methods study among Eritreans.
Spruijt I; Haile DT; Erkens C; van den Hof S; Goosen S; Ten Kate A; Teshome H; Karels M; Koenders M; Suurmond J
BMC Public Health; 2020 Mar; 20(1):315. PubMed ID: 32164637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
